Esperion Therapeutics, Inc. Forecast, price target & analysts
Esperion Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Esperion Therapeutics, Inc. Classifications & Recommendation:
Esperion Therapeutics, Inc. Price Target
| Target Price | $4.08 |
| Price | $3.66 |
| Potential |
11.48%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Esperion Therapeutics, Inc. 2026 .
The average Esperion Therapeutics, Inc. target price is $4.08.
This is
11.48%
register free of charge
$16.80
359.02%
register free of charge
$1.74
52.54%
register free of charge
|
|
| A rating was issued by 14 analysts: 10 Analysts recommend Esperion Therapeutics, Inc. to buy, 3 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Esperion Therapeutics, Inc. stock has an average upside potential 2026 of
11.48%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 332.31 | 394.90 |
| 185.66% | 18.83% | |
| EBITDA Margin | 16.39% | -14.62% |
| 112.27% | 189.19% | |
| Net Margin | -15.57% | -0.37% |
| 91.34% | 97.62% |
10 Analysts have issued a sales forecast Esperion Therapeutics, Inc. 2025 . The average Esperion Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Esperion Therapeutics, Inc. EBITDA forecast 2025. The average Esperion Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 Esperion Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Esperion Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.28 | -0.01 |
| 86.21% | 96.43% | |
| P/E | negative | |
| EV/Sales | 2.75 |
10 Analysts have issued a Esperion Therapeutics, Inc. forecast for earnings per share. The average Esperion Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Esperion Therapeutics, Inc....
Current Esperion Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Piper Sandler |
Locked
➜
Locked
|
Locked | Nov 25 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 19 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 17 2025 |
| Needham |
Locked
➜
Locked
|
Locked | May 07 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Apr 25 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 25 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Apr 17 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Nov 25 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 19 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 17 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Apr 25 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 25 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Apr 17 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
